Kairos Pharma to Showcase Oncology Pipeline at 2026 Investor Conference
January 20, 2026 — Kairos Pharma (KAPA) announces participation in the DealFlow Discovery Conference in 2026, featuring its clinical-stage oncology programs and lead candidate ENV-105 targeting drug resistance in cancer.